135 related articles for article (PubMed ID: 37006124)
1. Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab.
Tamamoto-Mochizuki C; Crawford N; Eder JM; Gonzales AJ; Olivry T
Vet Dermatol; 2023 Aug; 34(4):327-338. PubMed ID: 37006124
[TBL] [Abstract][Full Text] [Related]
2. Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
Calesso JR; Marques VS; de Carvalho OV; Costa-Val AP
Pol J Vet Sci; 2023 Jun; 26(2):231-238. PubMed ID: 37389418
[TBL] [Abstract][Full Text] [Related]
3. Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares?
Tamamoto-Mochizuki C; Paps JS; Olivry T
Vet Dermatol; 2019 Jan; ():. PubMed ID: 30672050
[TBL] [Abstract][Full Text] [Related]
4. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
[TBL] [Abstract][Full Text] [Related]
5. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Moyaert H; Van Brussel L; Borowski S; Escalada M; Mahabir SP; Walters RR; Stegemann MR
Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
[TBL] [Abstract][Full Text] [Related]
6. Early Activation of Th2/Th22 Inflammatory and Pruritogenic Pathways in Acute Canine Atopic Dermatitis Skin Lesions.
Olivry T; Mayhew D; Paps JS; Linder KE; Peredo C; Rajpal D; Hofland H; Cote-Sierra J
J Invest Dermatol; 2016 Oct; 136(10):1961-1969. PubMed ID: 27342734
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
Souza CP; Rosychuk RAW; Contreras ET; Schissler JR; Simpson AC
Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223
[TBL] [Abstract][Full Text] [Related]
8. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
Michels GM; Walsh KF; Kryda KA; Mahabir SP; Walters RR; Hoevers JD; Martinon OM
Vet Dermatol; 2016 Dec; 27(6):505-e136. PubMed ID: 27647513
[TBL] [Abstract][Full Text] [Related]
9. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
[TBL] [Abstract][Full Text] [Related]
10. IL-31 and IL-31 receptor expression in acute experimental canine atopic dermatitis skin lesions.
Tamamoto-Mochizuki C; Olivry T
Vet Dermatol; 2021 Dec; 32(6):631-e169. PubMed ID: 34796564
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of superficial epidermal adhesion molecules in an experimental dog model of acute atopic dermatitis skin lesions.
Olivry T; Dunston SM
Vet Dermatol; 2015 Feb; 26(1):53-6, e-17-8. PubMed ID: 25496350
[TBL] [Abstract][Full Text] [Related]
12. Pilot investigation of a model for canine atopic dermatitis: environmental house dust mite challenge of high-IgE-producing beagles, mite hypersensitive dogs with atopic dermatitis and normal dogs.
Marsella R; Olivry T; Nicklin C; Lopez J
Vet Dermatol; 2006 Feb; 17(1):24-35. PubMed ID: 16412117
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis.
Gonzales AJ; Humphrey WR; Messamore JE; Fleck TJ; Fici GJ; Shelly JA; Teel JF; Bammert GF; Dunham SA; Fuller TE; McCall RB
Vet Dermatol; 2013 Feb; 24(1):48-53.e11-2. PubMed ID: 23331679
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis.
Majewska A; Gajewska M; Dembele K; Maciejewski H; Prostek A; Jank M
BMC Vet Res; 2016 Aug; 12(1):174. PubMed ID: 27553600
[TBL] [Abstract][Full Text] [Related]
15. Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs.
Krautmann M; Walters RR; King VL; Esch K; Mahabir SP; Gonzales A; Dominowski PJ; Sly L; Mwangi D; Foss DL; Rai S; Messamore JE; Gagnon G; Schoell A; Dunham SA; Martinon OM
Vet Immunol Immunopathol; 2023 Apr; 258():110574. PubMed ID: 36842258
[TBL] [Abstract][Full Text] [Related]
16. Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ; Norris LR; Mahabir S; Walters RR; Martinon O; Dunham SA; Gonzales AJ
Vet Dermatol; 2021 Dec; 32(6):681-e182. PubMed ID: 33830571
[TBL] [Abstract][Full Text] [Related]
17. Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E; Videmont E
Vet Dermatol; 2022 Feb; 33(1):68-e22. PubMed ID: 34414621
[TBL] [Abstract][Full Text] [Related]
18. Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells.
McCandless EE; Rugg CA; Fici GJ; Messamore JE; Aleo MM; Gonzales AJ
Vet Immunol Immunopathol; 2014 Jan; 157(1-2):42-8. PubMed ID: 24321252
[TBL] [Abstract][Full Text] [Related]
19. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
Van Brussel L; Moyaert H; Escalada M; Mahabir SP; Stegemann MR
Vet Dermatol; 2021 Oct; 32(5):477-e131. PubMed ID: 34180084
[TBL] [Abstract][Full Text] [Related]
20. Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis.
Nuttall TJ; Knight PA; McAleese SM; Lamb JR; Hill PB
Clin Exp Allergy; 2002 May; 32(5):789-95. PubMed ID: 11994107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
